Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients

Child's Nervous System

Volumn 29, Issue 10, 2013, Pages 1851-1858

  Kim, Hyery ^a,b   Kang, Hyoung Jin ^a   Lee, Ji Won ^a   Park, June Dong ^a   Park, Kyung Duk ^a   Shin, Hee Young ^a   Ahn, Hyo Seop ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

Author keywords

Brain tumor; Chemotherapy; Irinotecan; Pediatrics; Salvage therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IRINOTECAN; MELPHALAN; THIOTEPA; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; INFECTIOUS COMPLICATION; LONG TERM SURVIVAL; MEDICAL RECORD REVIEW; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; NEUTROPENIA; OUTCOME ASSESSMENT; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHEMORADIOTHERAPY; CHILD; CHILD, PRESCHOOL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; MALE; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; RADIOTHERAPY; RETROSPECTIVE STUDIES; SALVAGE THERAPY; VINCRISTINE; YOUNG ADULT;

EID: 84884353858     PISSN: 02567040     EISSN: 14330350     Source Type: Journal    
DOI: 10.1007/s00381-013-2163-z     Document Type: Article

References (36)

1. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13(1):210-221
2. Aguilera D, Mazewski C, Fangusaro J, Macdonald TJ, McNall-Knapp RY, Hayes LL, Kim S, Castellino RC (2013) Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Child's nervous system: ChNS: official journal of the International Society for Pediatric Neurosurgery 29(4):589-596. doi: 10.1007/s00381-012-2013-4
3. Arbuck SG, Takimoto CH (1998) An overview of topoisomerase I-targeting agents. Semin Hematol 35(3 Suppl 4):3-12
4. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, Longee D (1996) Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14(6):1922-1927
5. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M (2001) A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 7(1):32-37
6. Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 25(29):4622-4627. doi: 10.1200/JCO.2007.11.6103
7. Bouffet E, Doz F, Demaille MC, Tron P, Roche H, Plantaz D, Thyss A, Stephan JL, Lejars O, Sariban E, Buclon M, Zucker JM, Brunat-Mentigny M, Bernard JL, Gentet JC (1998) Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse? Br J Cancer 77(8):1321-1326
8. Chang CH, Housepian EM, Herbert C Jr (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93(6):1351-1359
9. Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41(6):485-490
10. Dunkel IJ, Gardner SL, Garvin JH Jr, Goldman S, Shi W, Finlay JL (2010) High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro Oncol 12(3):297-303. doi: 10.1093/neuonc/nop031
11. Finlay JL (1996) The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors. Bone marrow transplant 18(Suppl 3):S1-S5
12. Finlay JL (1999) The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors: a reappraisal. Pediatr Transplant 3(Suppl 1):87-95
13. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD (1990) Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial. Cancer 66(12):2465-2469
14. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA, Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D, Radcliffe J, Tao ML, Shiminski-Maher T (2005) Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23(30):7621-7631. doi: 10.1200/JCO.2005.09.095
15. Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ (2010) Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr blood & cancer 54(4):591-595. doi: 10.1002/pbc.22347
16. Grodman H, Wolfe L, Kretschmar C (2009) Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. Pediatr blood & cancer 53(1):33-36. doi: 10.1002/pbc.21985
17. Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39(3):187-191
18. Kim SY, Sung KW, Hah JO, Koo HH, Kang HJ, Park KD (2010) Reduced-dose craniospinal radiotherapy followed by high-dose chemotherapy and autologous stem cell rescue for children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor. The Korean J of Hematol 45(2):120-126
19. Levy AS, Meyers PA, Wexler LH, Jakacki R, Angiolillo A, Ringuette SN, Cohen MB, Gorlick R (2009) Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer 115(1):207-216. doi: 10.1002/cncr.23992
20. Lisby M, Krogh BO, Boege F, Westergaard O, Knudsen BR (1998) Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase I catalysis. Biochemistry 37(30):10815-10827. doi: 10.1021/bi980757r
21. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280
22. Panosyan EH, Ikeda AK, Chang VY, Laks DR, Reeb CL, Bowles LV, Lasky JL, 3rd, Moore TB (2011) High-dose chemotherapy with autologous hematopoietic stem-cell rescue for pediatric brain tumor patients: a single institution experience from UCLA. Journal of Transplantation 2011:740673. doi: 10.1155/2011/740673
23. Park JE, Kang J, Yoo KH, Sung KW, Koo HH, Limdo H, Shin HJ, Kang HJ, Park KD, Shin HY, Kim IH, Cho BK, Im HJ, Seo JJ, Park HJ, Park BK, Ahn HS (2010) Efficacy of high-dose chemotherapy and autologous stem cell transplantation in patients with relapsed medulloblastoma: a report on the Korean Society for Pediatric Neuro-Oncology (KSPNO)-S-053 study. J Korean Med Sci 25(8):1160-1166. doi: 10.3346/jkms.2010.25.8.1160
24. Pendergrass TW, Milstein JM, Geyer JR, Mulne AF, Kosnik EJ, Morris JD, Heideman RL, Ruymann FB, Stuntz JT, Bleyer WA (1987) Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 5(8):1221-1231
25. Pourquier P, Kohlhagen G, Ueng LM, Pommier Y (1999) Topoisomerase I and II activity assays. Methods Mol Med 28:95-110. doi: 10.1385/1-59259-687-8:95
26. Ratain MJ (2000) Insights into the pharmacokinetics and pharmacodynamics of irinotecan. Clin Cancer Res 6(9):3393-3394
27. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279(5356):1504-1513
28. Shih CS, Hale GA, Gronewold L, Tong X, Laningham FH, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M (2008) High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 112(6):1345-1353. doi: 10.1002/cncr.23305
29. Shin HY (2005) Korean Society for Pediatric Neuro-Oncology (KSPNO). Korean J of Pediatr Hematol-Oncol 12(2):175-187
30. Sung KW, Yoo KH, Cho EJ, Koo HH, Lim do H, Shin HJ, Ahn SD, Ra YS, Choi ES, Ghim TT (2007) High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr blood & cancer 48(4):408-415. doi: 10.1002/pbc.21064
31. Torres CF, Rebsamen S, Silber JH, Sutton LN, Bilaniuk LT, Zimmerman RA, Goldwein JW, Phillips PC, Lange BJ (1994) Surveillance scanning of children with medulloblastoma. N Engl J Med 330(13):892-895. doi: 10.1056/NEJM199403313301303
32. Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS (2002) Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol 4(2):102-108
33. Vassal G, Boland I, Santos A, Bissery MC, Terrier-Lacombe MJ, Morizet J, Sainte-Rose C, Lellouch-Tubiana A, Kalifa C, Gouyette A (1997) Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 73(1):156-163. doi: 10.1002
34. Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, O'Quigley J, Germa C, Risse ML, Mignard D, Pein F (2003) A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21(20):3844-3852. doi: 10.1200/JCO.2003.08.175
35. Walker DA, Wilne S (2005) Treatment of medulloblastoma in young children. The lancet oncol 6(8):541-542. doi: 10.1016/S1470-2045(05)70259-X
36. Yule SM, Foreman NK, Mitchell C, Gouldon N, May P, McDowell HP (1997) High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study. J Clin Oncol 15(10):3258-3265